secwatch / observer
8-K filed April 19, 2023, 7:59 PM ET ticker IMRX CIK 0001790340
other material confidence high sentiment neutral materiality 0.60

Immuneering announces $27.8M public offering of 2.73M shares at $11.00/share

Immuneering Corp

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immuneering Corp entered into Underwriting Agreement with Jefferies LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters valued at approximately $27.8 million (effective 2023-04-18).

Action
entry
Agreement
underwriting
Counterparty
Jefferies LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters
Value
approximately $27.8 million
Effective
2023-04-18
Exact text from the filing
On April 18, 2023, Immuneering Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule I attached thereto (the “Underwriters”), in connection with the public offering, issuance and sale by the Company of 2,727,273 shares of the Company’s Class A common stock, $0.001 par value per share (the “Common Stock”), at a public offering price of $11.00 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-266738) and a related prospectus supplement filed with the Securities and Exchange Commission (the “Offering”).
View on SEC.gov

24 material agreements filed in the last 30 days. Browse all material agreements →

Immuneering Corp filing history →

Source: SEC EDGAR
accession 0001104659-23-047191
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.